专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130012412A1 MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT 审中-公开
标题翻译：乳腺癌诊断标记，测试方法和测试包
公开(公告)号：US20130012412A1
公开(公告)日：2013-01-10
申请号：US13618415
申请日：2012-09-14
申请人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI
发明人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI
IPC分类号： C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178
摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.
摘要翻译：本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为简单，可靠性高。与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

2. 发明授权

US08173365B2 Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof 有权
标题翻译：抑制信号转导的方法，其中使用的信号转导抑制剂及其用途
公开(公告)号：US08173365B2
公开(公告)日：2012-05-08
申请号：US12294347
申请日：2007-03-23
申请人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
发明人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： G01N33/57484 , A61K38/00 , A61K48/00 , C07K14/47 , C12N9/1205 , C12Q1/6886 , C12Q2600/106 , G01N2800/52 , Y10S435/96 , Y10S435/968
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

3. 发明申请

US20100144830A1 CANCER CELL IDENTIFICATION MARKER AND CANCER CELL PROLIFERATION INHIBITOR 审中-公开
标题翻译：癌细胞鉴定标记和癌细胞增殖抑制剂
公开(公告)号：US20100144830A1
公开(公告)日：2010-06-10
申请号：US12441747
申请日：2007-09-19
申请人： Masahiko Kuroda
发明人： Masahiko Kuroda
IPC分类号： C12Q1/68 , C12Q1/04 , C07H21/02 , A61K31/7105
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011 , G01N33/57496
摘要： Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ.
摘要翻译：公开了可用于检测各种人类癌细胞并且其表达与细胞的恶性改变密切相关的鉴定标记物，以及基于通过抑制识别标志物表达抑制癌细胞增殖的人类癌症治疗用组合物。标记物是人异染色质蛋白1γ（HP1γ），癌症治疗用组合物包含抑制人HP1γ基因（例如人HP1γ的siRNA）表达的一种或多种。

4. 发明授权

US4234866A Centralized alarm system for vehicles 失效
标题翻译：车辆集中报警系统
公开(公告)号：US4234866A
公开(公告)日：1980-11-18
申请号：US956788
申请日：1978-11-01
申请人： Masahiko Kuroda , Eiji Ohsawa
发明人： Masahiko Kuroda , Eiji Ohsawa
IPC分类号： G08B25/00 , B60K35/00 , B60R16/02 , G07C5/08 , G08B19/00 , G08B23/00
CPC分类号： B60K35/00 , G07C5/0816 , G08B19/00
摘要： A centralized alarm sytem for warning of abnormalities in a plurality of components, in particular, for a vehicle, comprising, a plurality of sensors, each associated with a component for producing an abnormality signal when the associated component becomes abnormal, a control circuit connected to each of the sensors for producing a main indication signal when any one of the sensors produces an abnormality signal and for producing a local indication signal for each sensor producing an abnormality signal, and a plurality of local indicators, each associated with one of the sensors and connected to the control circuit being capable of producing a perceptable indication when an associated one of the sensors produces an abnormality signal. A main indicator is also connected to the control circuit for producing a perceptable indication when a main indication signal is produced by the control circuit with the control circuit including a systems check device for turning the main indicator on when a main indicator is produced in the control circuit. The control circuit also includes a component checking device for permitting individual activation of each local indicator when a corresponding local indication signal is produced.
摘要翻译：一种用于警告多个部件，特别是用于车辆的部件异常的集中报警系统，包括多个传感器，每个传感器与相关部件变得异常时用于产生异常信号的部件相关联，控制电路连接到每个传感器用于当任何一个传感器产生异常信号并产生用于产生异常信号的每个传感器的本地指示信号时产生主指示信号，以及多个局部指示器，每个传感器与传感器中的一个相关联，连接到控制电路，当相关联的一个传感器产生异常信号时，能够产生可感知的指示。当控制电路产生主指示信号时，主控指示器还连接到控制电路，控制电路包括用于在控制器中产生主指示器时转动主指示器的系统检查装置电路。控制电路还包括一个组件检查装置，用于当产生相应的本地指示信号时允许每个本地指示器的单独激活。

5. 发明申请

US20150315653A9 METHOD FOR INHIBITING SIGNALING MEDIATED BY ERBB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF 审中-公开
标题翻译：用于抑制ERBB2介导的信号传导的方法，用于其的信号抑制剂及其用途
公开(公告)号：US20150315653A9
公开(公告)日：2015-11-05
申请号：US12563241
申请日：2009-09-21
申请人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
发明人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
IPC分类号： C12Q1/68 , C07H21/00 , C12N15/63 , C07K16/00 , A61P35/00 , C12Q1/02 , C12N5/071 , C07K14/00
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K38/1709 , A61K39/39558 , A61K48/00 , C07K14/4703 , C07K16/32 , C07K2317/24 , C07K2319/02 , C12N9/1205 , C12Q2600/158 , G01N33/5011 , G01N33/5041 , G01N33/57407 , G01N33/57484 , G01N33/57492 , G01N2333/71 , A61K2300/00
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供一种抑制人细胞中ErbB2介导的信号传导途径的活化和用于其的信号传导抑制剂的方法。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。上述多肽可以直接引入细胞，或者可以将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于ErbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

6. 发明申请

US20140170648A1 CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT 有权
标题翻译：癌症标记，使用癌症标记评估癌症的方法和评估试剂
公开(公告)号：US20140170648A1
公开(公告)日：2014-06-19
申请号：US14039835
申请日：2013-09-27
申请人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
发明人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

7. 发明授权

US08632967B2 Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent 有权
标题翻译：癌症标记，通过使用癌症标记物评估癌症的方法和评估试剂
公开(公告)号：US08632967B2
公开(公告)日：2014-01-21
申请号：US13472190
申请日：2012-05-15
申请人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
发明人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

8. 发明申请

US20100062978A1 METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF 有权
标题翻译：用于抑制信号传输的方法，其使用的信号传输抑制剂及其用途
公开(公告)号：US20100062978A1
公开(公告)日：2010-03-11
申请号：US12294347
申请日：2007-03-23
申请人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
发明人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
IPC分类号： A61K38/16 , C12N5/08 , C07H21/00 , C07K14/00 , C07K7/08 , A61K31/7088 , C12Q1/68 , A61P35/00
CPC分类号： G01N33/57484 , A61K38/00 , A61K48/00 , C07K14/47 , C12N9/1205 , C12Q1/6886 , C12Q2600/106 , G01N2800/52 , Y10S435/96 , Y10S435/968
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

9. 发明授权

US07358350B2 Oncogene, recombinant protein derived therefrom, and uses thereof 有权
标题翻译：癌基因，从其衍生的重组蛋白及其用途
公开(公告)号：US07358350B2
公开(公告)日：2008-04-15
申请号：US10758562
申请日：2004-01-16
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： C07H21/02 , C07H21/04
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。 1，特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。 2号

10. 发明申请

US20140178874A1 METHOD FOR EVALUATING CANCER 审中-公开
标题翻译：癌症评估方法
公开(公告)号：US20140178874A1
公开(公告)日：2014-06-26
申请号：US14032651
申请日：2013-09-20
申请人： Masahiko KURODA , Akira SAITO , Maki SANO
发明人： Masahiko KURODA , Akira SAITO , Maki SANO
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
摘要翻译：提供了一种使用新型癌症标志物评价受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。作为检测癌症标记物的方法，优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式